

国内版国际版

Microsoft Bing

Real World Evidence on First and Second Line Palliative Chemother.

Sign in

ALLIMAGESVIDEOS

195,000 ResultsAny time

Real World Evidence on Second-Line Palliative ...

<https://pubmed.ncbi.nlm.nih.gov/32850339>

Results: A total of 509 patients received first-line palliative chemotherapy, and of these 167 (33%) received at least one dose of second-line therapy and formed the final study population. Median OS2 was 5.2 months (95% CI = 4.7-5.7) and median TTF2 was 1.9 months (1.5-2.2).

Author: Emma Gränsmark, Nellie Bågenholm ... Publish Year: 2020

Frontiers | Real World Evidence on Second-Line Palliative ...

<https://www.frontiersin.org/articles/10.3389/fonc.2020.01176>

Jul 27, 2020 Results: A total of 509 patients received first-line palliative chemotherapy, and of these 167 (33%) received at least one dose of second-line therapy and formed the final study population. Median OS2 was 5.2 months (95% CI = 4.7-5.7) and median TTF2 was 1.9 months (1.5-2.2).

Author: Emma Gränsmark, Nellie Bågenholm ... Publish Year: 2020

Search Tools

Turn off Hover Translation (关闭取词)

ALL IMAGES VIDEOS

146,000 Results Any time

Real World Evidence on Second-Line Palliative Chemotherapy ...

<https://pubmed.ncbi.nlm.nih.gov/32850339>

Background: The outcome and tolerability of palliative second line chemotherapy for advanced pancreatic cancer (APC) in real life patients are largely unknown. Prognostic parameters for risk stratification and treatment guidance are lacking. Materials and Methods: A population based multicenter retrospective cohort study was conducted, covering all APC patients who received palliative second ...

Cited by: 1 Author: Emma Gr nsm r, Nellie B genholm Bylin, ...
Publish Year: 2020

Search Tools

[Turn off Hover Translation \(关闭翻译\)](#)

Frontiers | Real World Evidence on Second-Line Palliative ...

<https://www.frontiersin.org/articles/10.3389/fonc.2020.01176>

Jul 27, 2020 - Results: A total of 509 patients received first-line palliative chemotherapy, and of these 167 (33%) received at least one dose of second-line therapy and formed the final study population. Median OS2 was 5.2 months (95% CI = 4.7-5.7) and median TTF2 was 1.9 months (1.5-2.2).

Cited by: 1 Author: Emma Gr nsm r, Nellie B genholm Bylin, ...
Publish Year: 2020

PEOPLE ALSO ASK

Are there any second line therapies for pancreatic cancer?	▼
Which is the first treatment for pancreatic cancer?	▼
When did erlotinib stop being used for pancreatic cancer?	▼
What is the 5 year survival rate for pancreatic cancer?	▼

[Feedback](#)

Real world evidence on gemcitabine and nab ... - BMC Cancer

<https://bmccancer.biomedcentral.com/articles/10.1186/s12885-018-5244-2>

Jan 08, 2019 - This study confirms the effectiveness and safety of first-line Gem/NabP in both locally advanced and metastatic PDA in a real world setting. In the recent phase III trial IMPACT the combination of gemcitabine and nab-paclitaxel (Gem/NabP) showed increased overall survival compared to gemcitabine alone in the treatment of advanced pancreatic ductal adenocarcinoma (aPDA).

Cited by: 23 Author: Hakon Blomstrand, Ursula Scheibling, Char...
Publish Year: 2019 Estimated Reading Time: 11 mins

Text-Only Report

国内版

国际版

Real world evidence on first and second line palliative chemothera|



ALL

IMAGES

VIDEOS

133,000 Results

Any time ▾

Real World Evidence on Second-Line Palliative ...

<https://pubmed.ncbi.nlm.nih.gov/32850339>

Background: The outcome and tolerability of **palliative second line chemotherapy** for advanced **pancreatic cancer (APC)** in **real life** patients are largely unknown. Prognostic parameters for risk stratification and treatment guidance are lacking. Materials and Methods: A population based multicenter retrospective cohort study was conducted, covering all APC patients who received **palliative second ...**

Cited by: 1

Author: Emma Gränsmark, Nellie Bågenholm Byli...

Publish Year: 2020

Frontiers | Real World Evidence on Second-Line Palliative ...

<https://www.frontiersin.org/articles/10.3389/fonc.2020.01176> ▾

Jul 27, 2020 · Results: A total of 509 patients received **first-line palliative chemotherapy**, and of these 167 (33%) received at least one dose of **second-line therapy** and formed the final study population. Median OS2 was 5.2 months (95% CI = 4.7-5.7) and median TTF2 was 1.9 months (1.5-2.2).

Cited by: 1

Author: Emma Gränsmark, Nellie Bågenholm Byli...

Publish Year: 2020

PEOPLE ALSO ASK

Are there any second line therapies for pancreatic cancer? ▾

Which is the first treatment for pancreatic cancer? ▾

When did erlotinib stop being used for pancreatic cancer? ▾

What is the 5 year survival rate for pancreatic cancer? ▾

Feedback

Real world evidence on gemcitabine and nab ... - BMC Cancer

<https://bmccancer.biomedcentral.com/articles/10.1186/s12885-018-5244-2> ▾

Jan 08, 2019 · This study confirms the effectiveness and safety of **first-line Gem/NabP** in both locally **advanced** and metastatic PDA in a **real world** setting. In the recent phase III trial MPACT the combination of gemcitabine and nab-paclitaxel (Gem/NabP) showed increased overall survival compared